• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics General Medicine Classics

Tenofovir-emtricitabine more effective and safer than zidovudine-lamivudine in HIV treatment [Classics Series]

byAndrew Cheung, MD MBA
November 4, 2013
in General Medicine Classics, The Classics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. A significantly higher percentage of patients taking tenofovir, emtricitabine, and efavirenz had HIV viral load <50 copies/mL than those taking zidovudine, lamivudine, and efavirenz

2. Significantly more patients discontinued medication in the zidovudine-lamivudine group due to adverse events than in the tenofovir-emtricitabine group

Original Date of Publication: January 19, 2006

Study Rundown: Highly-active antiretroviral therapy (HAART) has significantly changed the clinical management and outcomes of HIV patients across the world. Prior to this study, zidovudine or tenofovir coupled with either lamivudine or emtricitabine, and efavirenz were the recommended HAART regimens. This 2006 paper took ART-naĂŻve and otherwise healthy HIV patients and randomly assigned them to either the tenofovir-emtricitabine regimen or the zidovudine-lamivudine regimen for 48 weeks and recorded the effects on viral load as well as adverse effects. In summary, they found that a significantly higher proportion of patients in the tenofovir-emtricitabine group achieved a viral load <50 copes/mL than their counterparts in the zidovudine-lamivudine group (80% vs. 70%, 95%CI 2.0-17.0%, P=0.02). More patients in the zidovudine-lamivudine group discontinued therapy due adverse effects, the most common being marked anemia. While the study was open-label, their primary and secondary objectives were all objective data, which reduces the impact of potential observer bias.

Click to read the study in NEJM

Relevant Reading (903 study): Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients

RELATED REPORTS

Long-acting cabotegravir significantly decreases incidence of HIV compared to daily oral tenofovir

Several factors influence health programs conducted in the African American Church

Liposomal amphotericin B noninferior to standard treatment for cryptococcal meningitis

Study Author, Dr. Joel Gallant, MD, MPH, talks to 2 Minute Medicine: Johns Hopkins University, Division of Infectious Disease.

“[This] 934 paper was definitely an important study in the history of antiretroviral therapy. For the first time, it demonstrated that AZT [zidovudine], which had been a cornerstone of treatment since the mid-1980’s, was less effective and more toxic than a comparator, in this case tenofovir.

The paper led to a change in treatment guidelines, which initially demoted AZT to the “alternative” category. Now it’s not even an alternative. The 903 and 934 studies signaled the end of an era in which toxicities like neuropathy, anemia, fatigue, and the dreaded lipoatrophy were virtually inevitable consequences of HIV therapy. Subsequent drug development led us to where we are today, with the majority of patients being treated with simple, well-tolerated, and highly effective regimens, usually given once a day, often with a single pill.”

In-Depth [randomized, controlled study]: This 2006 study published in NEJM was a multicenter, open-label, randomized controlled trial that assigned 500 patients with HIV to either the standard ART regimen of zidovudine, lamivudine, and efavirenz or to the newer drugs tenofovir, emtricitabine, and efavirenz for 48 weeks. All patients had been diagnosed with HIV and had never taken anti-viral therapy in the past. None of the participants had any other significant lab abnormalities. There was no cutoff CD4 count. Patients were followed for 48 weeks and viral load, CD4 count, standard labs, and adverse events were recorded. The primary outcome was reaching a viral load of equal or fewer than 400 copies/mL. The secondary outcomes included HIV RNA levels of less than 50 copies/mL, a positive trend in CD4 count, and the prevalence of adverse events.

The tenofovir-emtricitabine group surpassed the zidovudine-lamivudine group in the primary and all secondary outcomes. It had a significantly higher percentage of patients who achieved HIV RNA levels of less than 400 copies per milliliters (84% vs. 73%, 95%CI 4.0-19.0%, P=0.002) as well as less than 50 copies per milliliters (80% vs. 70%, 95%CI 2.0-17.0%, P=0.02) than those in the zidovudine-lamivudine group. Those patients also had a significant increase in their CD4 cell counts (190 vs. 158 cells; 95%CI 9-55; P=0.002) and fewer significant adverse effects from the drugs. There was also lower incidence of resistance development in the tenofovir-emtricitabine group compared to the zidovudine-lamivudine group.

By Milana Bogorodskaya and Andrew Cheung, M.D.

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: AIDSemtricitabineHIVlamivudineTenofovirzidovudine
Previous Post

Shared decision-making associated with increased parental resistance to vaccinations

Next Post

Home scoring system may prevent unnecessary pharyngitis clinic visits

RelatedReports

Gardasil vaccine demonstrates immunogenic response at 10-year follow-up
Chronic Disease

Long-acting cabotegravir significantly decreases incidence of HIV compared to daily oral tenofovir

May 18, 2022
Wellness

Several factors influence health programs conducted in the African American Church

May 18, 2022
Pre-exposure prophylaxis (PrEP) effective in preventing HIV infection in high-risk gay men
Chronic Disease

Liposomal amphotericin B noninferior to standard treatment for cryptococcal meningitis

March 29, 2022
Increased frailty associated with childhood cancer survivorship
Oncology

Pembrolizumab as a promising treatment in patients with classic or endemic Kaposi’s sarcoma

March 27, 2022
Next Post
Home scoring system may prevent unnecessary pharyngitis clinic visits

Home scoring system may prevent unnecessary pharyngitis clinic visits

Increased sleep linked to lower dietary intake in children

Increased sleep linked to lower dietary intake in children

Frequent meals linked with lower body weight in children and adolescents

Healthy dietary habits at midlife associated with better aging past 70

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Wellness Check: Mental Health
  • #VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma
  • #VisualAbstract: Pretreatment with radiotherapy and two cycles of concurrent cisplatin may reduce toxicity in locally advanced nasopharyngeal carcinoma
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.